Pumafentrine

Pumafentrine

SCHEMBL447418

CCOc1cc2c(cc1OC)C(c1ccc(C(=O)N(C(C)C)C(C)C)cc1)=NC1CCN(C)CC21

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE4D Q08499 2/20 1.00
PDE4A P27815 1/20 1.00
PDE4B Q07343 1/20 1.00
PDE4C Q08493 1/20 1.00
MCHR1 Q99705 3/20 0.36
CTSD P07339 1/20 0.34
HPGD P15428 1/20 0.34
L3MBTL1 Q9Y468 1/20 0.34
ATM Q13315 1/20 0.33
ALDH1A1 P00352 2/20 0.33
SMN1; SMN2 Q16637 2/20 0.33
KMT2A Q03164 2/20 0.33
MAPT P10636 2/20 0.33
KDM4E B2RXH2 1/20 0.33
LTB4R Q15722 1/20 0.33
MEN1 O00255 1/20 0.33
LMNA P02545 1/20 0.33
SRD5A2 P31213 1/20 0.33
RAB9A P51151 1/20 0.32
HRH3 Q9Y5N1 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7204721 1.00 PDE4D (1.00) PDE4DPDE4APDE4BPDE4CMCHR1
Pumafentrine SCHEMBL8344522 1.00 PDE4D (1.00) PDE4DPDE4APDE4BPDE4CMCHR1
Pumafentrine SCHEMBL26718 1.00 PDE4D (1.00) PDE4DPDE4APDE4BPDE4CMCHR1
Pumafentrine SCHEMBL29651667 1.00 PDE4D (1.00) PDE4DPDE4APDE4BPDE4CMCHR1
Pumafentrine SCHEMBL5187632 0.99 PDE4D (0.98) PDE4DPDE4APDE4BPDE4CMCHR1
Hydrochloric Acid SCHEMBL8388626 0.99 PDE4D (0.98) PDE4DPDE4APDE4BPDE4CMCHR1
Pumafentrine SCHEMBL5187638 0.99 PDE4D (0.98) PDE4DPDE4APDE4BPDE4CMCHR1
Hydrochloric Acid SCHEMBL8388627 0.99 PDE4D (0.98) PDE4DPDE4APDE4BPDE4CMCHR1
SCHEMBL7204406 0.97 PDE4D (0.94) PDE4DPDE4APDE4BPDE4CMCHR1
SCHEMBL7204724 0.97 PDE4D (0.94) PDE4DPDE4APDE4BPDE4CMCHR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 154 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050222193-A1 Novel combination for the treatment of airway disorders ALTANA PHARMA AG (DE) 2005-10-06 US claimed
US-20050165041-A1 Combination for the treatment of airway disorders ALTANA PHARMA AG (DE) 2005-07-28 US claimed
EP-1517706-A2 COMBINATION OF A PROTON PUMP INHIBITOR AND A RESPIRATORY AGENT FOR THE TREATMENT OF RESPIRATORY DISEASES ALTANA Pharma AG (DE) 2005-03-30 EP claimed
WO-2003094968-A2 COMBINATION OF A PROTON PUMP INHIBITOR AND A RESPIRATORY AGENT FOR THE TREATMENT OF RESPIRATORY DISEASES ALTANA PHARMA AG (DE) 2003-11-20 WO claimed
EP-0937074-B1 BENZONAPHTHYRIDINES AS BRONCHIAL THERAPEUTICS ALTANA PHARMA AG (DE) 2003-03-12 EP claimed
US-6008215-A TREATING INFLAMMATORY AIRWAY DISORDERS BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH (DE) 1999-12-28 US claimed
US-11555040-B2 Oxepinopyrazole derivatives as inhibitors of P13-kinase activity GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2023-01-17 US disclosed
US-20220324875-A1 CHEMICAL COMPOUNDS GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2022-10-13 US disclosed
EP-1907037-B2 MEDICAMENT DISPENSER GLAXO GROUP LTD (GB) 2022-09-07 EP disclosed
EP-1962932-B1 MEDICAMENT DISPENSER GLAXO GROUP LTD (GB) 2021-09-08 EP disclosed
EP-3260453-B1 OXAZOLE SUBSTITUTED INDAZOLES AS PI3-KINASE INHIBITORS GLAXO GROUP LTD (GB) 2021-03-31 EP disclosed
EP-3414228-B1 CHEMICAL COMPOUNDS AS INHIBITORS OF KINASE ACTIVITY GLAXOSMITHKLINE IP DEV LTD (GB) 2020-03-18 EP disclosed
EP-1907037-B1 MEDICAMENT DISPENSER GLAXO GROUP LTD (GB) 2019-07-17 EP disclosed
WO-2003094967-A2 NEW COMBINATION OF REVERSIBLE PROTON PUMP INHIBITORS AND AIRWAY THERAPEUTICS FOR TREATING AIRWAY DISORDERS ALTANA PHARMA AG (DE) 2003-11-20 WO disclosed
WO-2003094968-A2 COMBINATION OF A PROTON PUMP INHIBITOR AND A RESPIRATORY AGENT FOR THE TREATMENT OF RESPIRATORY DISEASES ALTANA PHARMA AG (DE) 2003-11-20 WO disclosed
EP-1341527-A1 PHARMACEUTICAL PREPARATION COMPRISING AN ACTIVE DISPERSED ON A MATRIX ALTANA Pharma AG (DE) 2003-09-10 EP disclosed
WO-2003024488-A2 COMBINATION OF A PDE INHIBITOR AND A LEUKOTRIENE RECEPTOR ANTAGONIST ALTANA PHARMA AG (DE) 2003-03-27 WO disclosed
EP-0937074-B1 BENZONAPHTHYRIDINES AS BRONCHIAL THERAPEUTICS ALTANA PHARMA AG (DE) 2003-03-12 EP disclosed
WO-2002045693-A1 PHARMACEUTICAL PREPARATION COMPRISING AN ACTIVE DISPERSED ON A MATRIX ALTANA PHARMA AG (DE) 2002-06-13 WO disclosed
US-6008215-A TREATING INFLAMMATORY AIRWAY DISORDERS BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH (DE) 1999-12-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220324875-A1 CHEMICAL COMPOUNDS PIK3CA, PIK3CD, PIK3CB PDE4D 1068/4885PDE4A 1096/4885PDE4B 844/4885
US-11555040-B2 Oxepinopyrazole derivatives as inhibitors of P13-kinase activity CDK3, CDK13, AKT3 PDE4D 547/4885PDE4A 576/4885PDE4B 716/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.